IPO Window Opens Wide: A $1B Sub Franchise and a Dozen Deals Hit the Tape

The late-July 2026 IPO calendar looks like a pressure valve releasing. After a first half where new-listing volume ran well below the pace markets saw in the 2021 cycle, the final week of July and first days of August are carrying the broadest and most diverse slate of operating-company IPOs in months — a $1 billion restaurant franchise, two clinical-stage biotechs approaching FDA decision dates, a sustainable-fashion brand, a nuclear-energy developer, and a cybersecurity company raising more than a billion on its own. The sheer breadth matters. When the IPO window narrows, issuers retreat to the safest sectors — usually software or pharma with a clear catalyst. When it opens wide enough to absorb a sub-sandwich chain and a nuclear play in the same week, the capital-markets plumbing is telling you something about risk appetite underneath the index level.

Jersey Mike’s Leads With a $1 Billion Deal

The largest operating-company IPO on the calendar this week is Jersey Mike’s Subs (JMKE), pricing on the NYSE on July 30. The offering of 43.5 million shares at a $21–$25 range targets roughly $1 billion in gross proceeds, with an implied market capitalization near $7.3 billion on $742 million in trailing revenue.^[1][2]

That is a restaurant IPO at a scale the market has not seen since the Cava-era casual-dining wave. The revenue base is real, the franchise model is proven, and the price range implies a mid-single-digit revenue multiple — not a growth-tech multiple, but a premium to where most publicly traded quick-service franchises change hands. The question is whether that premium holds on the first day of trading or whether the book-building process has already pulled the price range to the top of what the market will absorb. We won’t know until the first print, but the filing itself is a confidence signal: private-equity-backed franchise operators rarely bring a $1 billion deal unless they believe the bid is there.

Biotech Dominates the Calendar

Two biotech IPOs bookend the week and carry the most discrete catalysts:

Apnimed (APMD) — NASDAQ, July 31. The Massachusetts-based company is offering 10 million shares at $14–$16, targeting up to $160 million (with an overallotment option that could add another $24 million).^[3] The lead candidate, oxnimbi (AD109), is an oral therapy for obstructive sleep apnea — a condition affecting an estimated 936 million people worldwide. The FDA accepted the New Drug Application on July 14, with a PDUFA target date of February 28, 2027.^[3] If approved, oxnimbi would be the first oral drug to reach the OSA market, a space Eli Lilly’s Zepbound entered in 2024 for obese patients but which has no pharmaceutical option for non-obese sufferers.^[3] The IPO proceeds — approximately $228.8 million combined with existing cash — are earmarked for the regulatory push and potential commercialization.^[3]

Attovia Therapeutics (ATTO) — NASDAQ, August 5. The San Carlos, California biotech plans to sell 12.5 million shares at $15–$17, raising as much as $212.5 million at a market value near $655 million.^[4] Backed by a Goldman Sachs affiliate, Deep Track Capital, Frazier Life Sciences, and venBio, Attovia is developing precision biologics for immune-mediated diseases using its ATTOBODY platform — one drug targeting interleukin-31 that has completed Phase 1 dosing, and another targeting interleukin-13 expected to enter trials in the first half of 2027.^[4] The deal is led by Morgan Stanley, Leerink Partners, Citigroup, and RBC, with pricing expected August 4.^[4]

Both deals come at a time when biotech IPO performance has been among the strongest in the new-listings category. Veradermics, which debuted in February, has returned roughly 534% since its IPO, while Hemab Therapeutics has gained about 149% since its May listing.^[4] That track record is a tailwind for the book-build — but it also sets a high bar. The trajectory I’m watching is whether institutional demand for clinical-stage biotech is deep enough to absorb two $150–$200 million deals in the same week, or whether one crowds out the other.

The Broader Slate: Cyber, Nuclear, Fashion, and Gene Editing

Beyond the two biotechs and the sub-sandwich chain, the late-July calendar carries several other operating-company IPOs that together paint a picture of sector breadth:

Sources: Stock Analysis IPO calendar and MarketBeat IPO calendar.^[1][2] Deal sizes are calculated at the midpoint of stated price ranges. All dates and terms are estimated and subject to change.

The CsquareX deal (CSQR) is the single largest on the calendar at approximately $1.25 billion — 50 million shares at $23–$27 on the NYSE, pricing July 16.^[2] Standard Nuclear (STDN) is raising roughly $195 million for nuclear-energy development, also on the NYSE.^[2] Reformation, the sustainable-fashion brand, is targeting roughly $210–$225 million on the NYSE.^[1][2] Scribe Therapeutics (SCTX), a gene-editing company, is raising approximately $120 million on NASDAQ.^[2]

Seven operating-company IPOs across five distinct sectors in a two-week window. That is not a trickle. It is the kind of issuance density that either signals a durable reopening or a sprint to beat a closing window — and the distinction matters for what comes next.

SPACs Fill the Background

Layered beneath the operating-company deals is a steady stream of blank-check listings. At least eight SPACs priced or are set to price in the same July window — East West Ave Acquisition (EWAV), AMR Resources Acquisition (AMACU), BR Technology Merger (BRTMU), Southern Cross Acquisition I (NCOU), Pelican Acquisition (PLCIU), Market Technology Acquisition (MTAKU), Catalyst Acquisition (CATLU), and BOA Acquisition Corp. II (THEO) — each raising $75–$325 million at the standard $10 unit price.^[2]

SPAC volume on its own is not a market signal the way it was in 2021, when de-SPAC mergers drove retail speculation. But the fact that sponsors are once again able to raise $200–$300 million per vehicle, in volume, alongside a healthy operating-company calendar tells us the demand side is not the bottleneck. There is enough investor appetite to absorb both speculative and revenue-backed issuance simultaneously.

Market-Structure Backdrop

The reopening comes against a backdrop of returning volatility. MarketBeat flagged “volatility is back” in a July 26 analysis of market tollbooth operators positioned to profit from choppier conditions,^[2] and recent headlines have pointed to sharp corrections in space stocks^[2] and mixed signals from bank earnings and semiconductor names. The market indexes have been approaching overbought territory on momentum measures, a condition that has historically preceded pauses.^[5]

The base-rate case here is mixed. In most cycles, a sharp pick-up in IPO issuance coincides with a market that has run enough to give issuers confidence — but the strongest issuance windows tend to come just before a correction, not after. The 2021 IPO boom peaked in February of that year, roughly two months before the growth-stock correction that punished newly listed names. That is a single data point, not a law, but it is the one most relevant to the current setup: a broad, diverse calendar at elevated index levels, with volatility rising.

Put a number on it: I’d put the probability that this calendar represents a durable six-month reopening at roughly 60%, with the 40% case being a one-quarter sprint that fades if volatility spikes or a macro shock — rate-sensitive, geopolitical, or earnings-driven — forces issuers back to the sidelines. The structure of the deals matters for which side wins. Jersey Mike’s and CsquareX are revenue-backed, not story stocks; they can price into a choppy market if the valuation is reasonable. Apnimed and Attovia, by contrast, are trading on clinical catalysts that are months away, and their aftermarket performance will depend heavily on broader biotech sentiment through the fall.

What to Watch Next

1. Jersey Mike’s first-day performance (July 30). A $1 billion restaurant-franchise IPO is a rarity. If it prices at the top of the range and trades up, the signal is that institutional capital is hungry for revenue-backed, profitable consumer businesses at premium valuations. If it prices below range or breaks issue price on day one, the window is narrower than the calendar suggests.

2. Apnimed’s FDA timeline. The NDA was accepted July 14 with a PDUFA date of February 28, 2027.^[3] Between now and that date, any AdCom scheduling, complete-response letters, or competitor moves (e.g., Lilly expanding Zepbound’s OSA label) will move the aftermarket. This is the single highest-impact catalyst in the current IPO cohort.

3. Attovia’s pricing and first-day reaction (August 4–5). As the last deal in the cluster, Attovia’s reception will tell us whether the biotech bid is deep enough to absorb back-to-back $150–$200 million clinical-stage offerings, or whether the calendar is crowding itself out.^[4]

4. The August–September pipeline. No IPOs are currently scheduled beyond Attovia on August 5.^[1] The pace at which new S-1 filings populate the calendar in the first two weeks of August will indicate whether this week’s breadth is the start of a sustained reopening or a midsummer cluster that burns out.

5. VIX and index momentum. The late-July volatility uptick and overbought momentum readings^[2][5] are the backdrop against which all of these deals will trade. A VIX spike above the recent range into mid-August would compress the window faster than any individual deal can signal.

The late-July 2026 IPO cluster is the most concrete evidence yet that the new-listings market has unfrozen. The breadth — restaurants, biotech, cybersecurity, nuclear, fashion, gene editing — is genuine. But breadth at a market top is the oldest warning in the IPO playbook, and the calendar is still thin beyond the first week of August. The trajectory is positive; the uncertainty is whether it persists. Watch the first prints.